Send page
    20 Sep 2011

    Wistrand advises Bluefish Pharmaceuticals

    Pharmaceutical company Bluefish Pharmaceuticals AB has acquired BMM Pharma AB, a subsidiary of BioPhausia AB.


    The portfolio acquired includes 19 pharmaceutical products, of which most are used in pain, inflammation and gastrointestinal therapy. Following the acquisition, Bluefish now has 68 products in its portfolio, of which 41 have already been launched.


    The acquisition is expected to increase net sales by approximately SEK 30 million. No personnel are included in the acquisition. The acquisition will be financed by means of a bridging loan from Färna Invest AB, which has also entered into an agreement for a new share issue.


    Bluefish Pharmaceuticals was founded in 2005 and focuses on the development, manufacture and sale of generic pharmaceuticals.

    Wistrand advised Bluefish in the acquisition, primarily through partners Lars hasp and Magnus Forssman.


    For further information:
    Magnus Forssman, partner Wistrand
    Direct: +46 8 50 72 0069
    Mobile: +46 709 50 72 69


    15 May 2017
    Wistrand advises in connection with the ...
    08 May 2017
    Wistrand advises Strawberry Properties o...
    28 Apr 2017
    Legal 500’s rankings for 2017 – Wistrand...
    11 Apr 2017
    Chambers Europe 2017 – Wistrand still hi...
    11 Apr 2017
    Wistrand advises Nokas on its acquisitio...
    04 Apr 2017
    Wistrand advises SBB on its acquisitions...
    04 Apr 2017
    Wistrand advises SBB in connection with ...
    30 Mar 2017
    Wistrand advises SBB in connection with ...
    29 Mar 2017
    Wistrand advises Nordic Choice Hotels on...
    23 Mar 2017
    Wistrand advises SBB on its acquisition ...
    20 Feb 2017
    Erik Ullberg in the current GALA Gazette
    09 Jan 2017
    Wistrand has advised on the transfer of ...